WO2025253352 - METHODS FOR PROMOTING HEPATIC REGENERATION
National phase entry is expected:
Publication Number
WO/2025/253352
Publication Date
11.12.2025
International Application No.
PCT/IB2025/055855
International Filing Date
06.06.2025
Title **
[English]
METHODS FOR PROMOTING HEPATIC REGENERATION
[French]
PROCÉDÉS POUR FAVORISER LA RÉGÉNÉRATION HÉPATIQUE
Applicants **
CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET)
ASOCIACIÓN CIVIL DE ESTUDIOS SUPERIORES (ACES)-UNIVERSIDAD AUSTRAL
HZ4 LIVER INC.
METON INC.
Inventors
MAZZOLINI, Guillermo
BAYO FINA, Juan Miguel
FIORE, Esteban Juan
BUENLONI, Barbara
BOLLINI, Mariela
DANA, Alejandro Leonel
CRISTÓFALO, Alejandro Esequiel
Priority Data
63/657,472
07.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3064 | |
| EPO | Filing, Examination, Granting | 22055 | |
| Japan | Filing, Examination, Granting | 2677 | |
| South Korea | Filing, Examination, Granting | 3266 | |
| USA | Filing, Examination, Granting | 9110 |
Total:
40,172
Contact Us
Abstract[English]
The present disclosure provides a method for in vivo liver regeneration in a subject in need thereof, comprising: administering to the subject a compound of formula (I): (I), or a pharmaceutically acceptable salt thereof, or a co-crystal thereof. The present disclosure also provides a method for ex vivo liver regeneration, comprising: applying to an ex vivo liver graft the compound of formula (I), or the pharmaceutically acceptable salt thereof, or the co- crystal thereof. The present disclosure also provides a method of treating a liver disorder for a subject in need thereof, comprising: administering to the subject a therapeutically effective dose of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a cocrystal thereof. The present disclosure also provides a dihydrochloride salt form of the compound of formula (I). The present disclosure also provides a co-crystal including the dihydrochloride salt form of the compound of formula (I) and a co-crystal former selected from succinic acid and adipic acid.[French]
La présente divulgation concerne un procédé de régénération hépatique in vivo chez un sujet en ayant besoin, comprenant : l'administration au sujet d'un composé de formule (I) : (I), ou un sel pharmaceutiquement acceptable ou un co-cristal de celui-ci. La présente divulgation concerne également un procédé de régénération hépatique ex vivo, comprenant : l'application à un greffon hépatique ex vivo du composé de formule (I), ou du sel pharmaceutiquement acceptable ou du co-cristal de celui-ci. La présente divulgation concerne également une méthode de traitement d'un trouble hépatique pour un sujet en ayant besoin, comprenant : l'administration au sujet d'une dose thérapeutiquement efficace d'un composé de formule (I), ou d'un sel pharmaceutiquement acceptable ou d'un co-cristal de celui-ci. La présente divulgation concerne en outre une forme de sel de dichlorhydrate du composé de formule (I). La présente divulgation concerne par ailleurs un co-cristal comprenant la forme de sel de dichlorhydrate du composé de formule (I) et un agent de formation de co-cristal choisi parmi l'acide succinique et l'acide adipique.